Urinary polycyclic aromatic hydrocarbon metabolites and hyperlipidemia: NHANES 2007–2016

Chenle Ye,Yuanrun Liu,Zhuoqi He,Weikai Huang,Guangzhan Chen,Tieli Peng,Kaishu Li
DOI: https://doi.org/10.1186/s12944-024-02153-6
2024-05-29
Lipids in Health and Disease
Abstract:The relationships between urinary polycyclic aromatic hydrocarbon (PAH) metabolites and hyperlipidemia have not been thoroughly studied. The primary goal of this research focused on investigating the linkage between PAH metabolite concentrations in urine and hyperlipidemia prevalence within US adults.
biochemistry & molecular biology,nutrition & dietetics
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the relationship between the concentrations of polycyclic aromatic hydrocarbon (PAH) metabolites in urine and the prevalence of hyperlipidemia. Specifically, the study aims to fill the knowledge gaps in previous research by analyzing the association between urinary PAH metabolite levels and the risk of hyperlipidemia in American adults. This helps to clarify the potential impact of environmental pollutants on health and provides public health - level support for the prevention of hyperlipidemia. ### Research Background - **Hyperlipidemia**: A systemic metabolic disorder characterized by one or more blood lipid components exceeding the normal threshold, affecting approximately 10% of adults. Hyperlipidemia is mainly manifested as elevated levels of low - density lipoprotein cholesterol (LDL - C) and plasma triglycerides (TGs), and these factors are important contributors to various diseases such as diabetes, hypertension, obesity, and non - alcoholic fatty liver disease. - **Polycyclic Aromatic Hydrocarbons (PAHs)**: A common class of environmental pollutants, originating from the incomplete combustion of organic substances, such as petroleum, tobacco, and fossil fuels, as well as the cooking process of food. The main routes of human exposure to PAHs include inhalation, ingestion, dermal contact, and placental transfer. PAHs have potential teratogenic, carcinogenic, and mutagenic effects, and their metabolites are usually excreted in urine. ### Research Objectives - **Explore the relationship between urinary PAH metabolite levels and the prevalence of hyperlipidemia**: Analyze the data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2016 to study the association between urinary PAH metabolite concentrations and the prevalence of hyperlipidemia. - **Evaluate the combined effect of multiple urinary PAH metabolite mixtures on hyperlipidemia**: Use the weighted quantile sum (WQS) regression analysis method to evaluate the combined effect of multiple urinary PAH metabolites on the risk of hyperlipidemia. ### Methods - **Study Cohort**: Data were obtained from NHANES from 2007 to 2016, and finally 7,030 participants were analyzed. - **Urinary PAH Metabolite Detection**: Use online solid - phase extraction - high - performance liquid chromatography - tandem mass spectrometry (online SPE - HPLC - MS/MS) technology to detect PAH metabolites in urine. - **Hyperlipidemia Assessment**: According to the criteria of NCEP ATP III, hyperlipidemia was assessed by laboratory testing of triglycerides (TGs), total cholesterol (TC), low - density lipoprotein cholesterol (LDL - C), and high - density lipoprotein cholesterol (HDL - C) in plasma. - **Statistical Analysis**: Use multivariate logistic regression analysis, restricted cubic spline (RCS) model, and weighted quantile sum (WQS) regression analysis to evaluate the relationship between urinary PAH metabolite levels and the risk of hyperlipidemia. ### Results - **Overall Results**: Individuals in the highest quintile of urinary PAH metabolite concentrations showed a significantly higher prevalence of hyperlipidemia (OR: 1.33, 95% CI: 1.01–1.75). - **Specific Metabolites**: The levels of 1 - hydroxynaphthalene and 2 - hydroxyfluorene in the higher quintiles were positively correlated with the prevalence of hyperlipidemia. - **WQS Model**: There was a positive correlation between the urinary PAH metabolite mixture and hyperlipidemia (OR = 1.04, 95% CI: 1.00 - 1.09), with 2 - hydroxynaphthalene contributing the most. ### Conclusions This study found through cross - sectional analysis that there is a significant correlation between urinary PAH metabolite concentrations and the prevalence of hyperlipidemia in the American population, especially the influence of 2 - hydroxynaphthalene is the most significant. These findings emphasize the importance of reducing PAH exposure as a measure to prevent hyperlipidemia.